Gilead Sciences has authorized a repurchase of up to $5 billion of the company’s common stock.
This is in addition to a separate $5 billion buyback program announced in January 2011, which has approximately $2.9 billion remaining in the plan and is expected to be completed by September 2014.
The new program expires three years after the completion of the current repurchase program.
For further financing deal information visit Current Agreements (subscription required)
Read: more on financing deals in pharma, biotech, life science partnering deal news, insights and glossary
View: Current Partnering’s Financing Scorecard – view top life science financing deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity